FDA Requests the Withdrawal of the Weight-loss Drug Lorcaserin from the Market – Potential Risk of Cancer Outweighs the Benefits

FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market Potential risk of cancer outweighs the benefits – U.S. Food & Drug Administration (free)

Source: Lorcaserin (Belviq ) Withdrawn From US Market Due to Cancer Risk – Medscape (free registration required)

Related: FDA Safety Communication: Possible Increased Risk of Cancer with Weight-loss Medicine Lorcaserin (free)